Navigation Links
Modified gene targets cancer cells a thousand times more often than healthy cells
Date:12/17/2008

d in DNA repair, which explains why it's more often expressed in cancer cells. Cancer cells reproduce at accelerated rates, often "not stopping to fix their DNA when they should," says Gorbunova. In these cancer cells, Rad51 is working overtime to repair all the damage, so it's not surprising that it is expressed more often.

Gorbunova believes that when she stripped out part of the Rad51-coding gene, she also stripped out some regulatory elements, which control the production of the protein. Without these elements, healthy cells ignore the gene and do not make the protein. However, these changes have opposite the effect on cancer cells, causing elevated, uncontrolled protein production.

Gobunova and her team have already fused a variant of diphtheria toxin into the Rad51 gene as a "toxic bomb" and tested it on a variety of cancer cell types, including breast cancer, fibrosarcoma, and cervical cancer cells. The results look very promising, she says.

"The early results show the new Rad51 killed all of the cancer cells with minimal if any effect on normal cells," says Gorbunova. "We're very excited. The results are much more striking than anything we would have guessed."

Gorbunova is now working with Stephen Dewhurst, professor of miocrobiology and immunology at the University of Rochester School of Medicine and Dentistry, to design a way to incorporate the new gene with its toxic cargo into a benign virus. If successful, the team will attempt to treat cancer in mice by injecting their tumors with a solution of the virus, and allow the virus to implant the gene into all cells. The key question is whether a dose high enough to kill the cancer cells also will be high enough to kill healthy cells in a living animal, despite the thousand-fold difference in the two cell types' levels of expression.

If the tests are successful, Gorbunova hopes the process might be someday given as a simple shot-in-the-arm, which might travel throughout the bloodstream an
'/>"/>

Contact: Jonathan Sherwood
jonathan.sherwood@rochester.edu
585-273-4726
University of Rochester
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
2. Technique used in human ankle injuries modified to treat dogs knees
3. Genetically modified carrots provide more calcium
4. Penn Veterinary Medicine report new strategy to create genetically-modified animals
5. UQ research targets West Nile virus and dengue fever
6. New genes present drug targets for managing cholesterol and glucose levels
7. First comprehensive genomic study of common cold reveals new treatment targets
8. US Air Force grant targets medical evacuation procedures
9. Viral magic bullet targets cancer cells with help of new compound
10. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
11. N.Y. research team discovers how antidepressants and cocaine interact with brain cell targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... of how plants "breathe" may help us breed and select ... of Toronto study. , The paper, which offers the first ... surface pores, appears in the July 12 issue of Current ... and senior author Malcolm Campbell. "This is a gene that ...
... intense selective logging stopped in the region now ... guenon (Cercophithecus ascanius) is a primate still in ... new study, changed the ecological balance for these ... door for multiple parasitic infections. , The researchers ...
... sneak past the blood brain barrier, which protects the brain ... particularly invasive brain cancer, according to a new Saint Louis ... Academy of Sciences Online Early Edition the week of Aug. ... drugs into the brain, you can cure brain cancer," says ...
Cached Biology News:Genetic discovery could lead to drought-resistant plants 2Logging changed ecological balance for monkeys, damaged health 2Logging changed ecological balance for monkeys, damaged health 3Slipping past the blood brain barrier: Research shows potential treatment for brain cancer 2
(Date:4/30/2015)... (PRWEB) April 30, 2015 Available ... at http://www.lespausa.com , Fleur’s ... product combining the benefits of makeup, skin care ... subtly tinted cream is designed with specific complexion-correcting ... an even complexion and a healthy glow. Far ...
(Date:4/30/2015)... Cordova, CA (PRWEB) April 30, 2015 ... announced that Julie I. Morris has joined SureClinical’s executive ... is an experienced biotech and technology executive with over ... large Fortune 500 companies. , Ms. Morris joins ... ag biotech company. She was CFO of MBI from ...
(Date:4/30/2015)... 2015 Sterlitech is proud to ... PX, PY, and PZ Polyacrylonotrile (PAN) membranes ... Designed to be ideal for oil removal ... fill critical process requirements where the presence of ... “New regulations on industrial wastewater discharge and quality ...
(Date:4/29/2015)... BELLINGHAM, Washington, and BALTIMORE, Maryland, USA (PRWEB) April 29, ... premier event for photonics, optical sensing, and imaging on ... a place for government program managers, researchers, applications developers, ... and technology of sensing and imaging for multiple applications. ... -- defense and security, and commercial and scientific sensing ...
Breaking Biology Technology:Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Sterlitech Offers New Ultrafiltration Membranes 2SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... CGCP), announced that the company will release results,for ... to market open on,Wednesday, November 14, 2007. The ... Senior Vice President and Chief Financial Officer William ... day at 12:00 p.m. Eastern,time (9:00 a.m. Pacific ...
... Oct. 24 Cell Therapeutics,Inc. (CTI) (Nasdaq ... at,the 19th annual AACR-NCI-EORTC Symposium show its ... refractory to currently,marketed platinum agents carboplatin, cisplatin ... trials in late 2008. "Bis-platinates represent ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... of approval from the U.K. Medicines and ... Trial Application (CTA) to begin,a clinical trial ... cyclophosphamide, a chemotherapeutic agent as well as,immune ...
Cached Biology Technology:Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
Request Info...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
supplied with 10x reaction buffer...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Biology Products: